PT  - JOURNAL ARTICLE
AU  - Sokoll, Paulo Roberto
AU  - Migliavaca, Celina Borges
AU  - Siebert, Uwe
AU  - Schmid, Daniela
AU  - Arvandi, Marjan
TI  - Prevalence of <em>Mycoplasma genitalium</em> infection among HIV PrEP users: a systematic review and meta-analysis
AID  - 10.1136/sextrans-2022-055687
DP  - 2023 Aug 01
TA  - Sexually Transmitted Infections
PG  - 351--359
VI  - 99
IP  - 5
4099  - http://sti.bmj.com/content/99/5/351.short
4100  - http://sti.bmj.com/content/99/5/351.full
SO  - Sex Transm Infect2023 Aug 01; 99
AB  - Objectives To summarise the prevalence of Mycoplasma genitalium (MG) and antibiotic-resistant MG infection among HIV pre-exposure prophylaxis (PrEP) users.Methods We searched MEDLINE, Embase, Web of Science and Global Index Medicus up to 30 September 2022. We included studies reporting the prevalence of MG and/or antibiotic-resistant MG infection among PrEP users. Two reviewers independently searched for studies and extracted data. A systematic review with random-effects meta-analysis was performed to quantitatively summarise the results of included studies. The critical appraisal of included studies was conducted with the Joanna Briggs Institute checklist for prevalence studies and the quality of evidence was assessed with Grading of Recommendations Assessment, Development and Evaluation (GRADE).Results A total of 15 studies were included in the systematic review, with 2341 individuals taking PrEP. Studies were conducted in high-income level countries between 2014 and 2019. Median age of participants varied from 23.5 to 40 years. The majority were men (85%) and among them, 93% were men who have sex with men. To identify MG, urine samples were analysed in 14 studies, rectal or anal swabs in 12 studies, oral or pharyngeal swabs in 9 studies, and urethral or vaginal in 3 studies. The pooled point prevalence of MG among PrEP users was 16.7% (95% CI 13.6% to 20.3%; 95% prediction interval (95% PI) 8.2% to 31.1%). The pooled point prevalence of macrolide-resistant infections was 82.6% (95% CI 70.1% to 90.6%; 95% PI 4.7% to 99.8%) and the prevalence of fluoroquinolone-resistant infections was 14.3% (95% CI 1.8% to 42.8%). Individuals taking PrEP have a higher chance of being infected with MG compared with those not taking PrEP (OR 2.30; 95% CI 1.6 to 3.4). The quality of evidence was very low to moderate.Conclusion We observed a high prevalence of MG and its macrolide resistance among PrEP users, highlighting the need to reinforce prevention strategies against sexually transmitted infections in this population.PROSPERO registration number CRD42022310597.All data relevant to the study are included in the article or uploaded as supplemental information.